Purpose: To evaluate the cost-utility of Luminopia and CureSight as therapy for amblyopia compared to current common amblyopic treatments such as glasses, atropine drops, and patching.
Design: Cost analysis based on data from published randomized control trials (RCTs).
Subjects: None; based on data from the Luminopia, CureSight and atropine RCTs.